Refractory thyroid carcinoma: which systemic treatment to use?
| Autor: | Lionel D'Hondt, Luc Michel, Julien Lemaire, Laurence Faugeras, Anne-Sophie Pirson, Julian Donckier, Sebastien Vandervorst |
|---|---|
| Přispěvatelé: | UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation, UCL - SSS/IREC/EDIN - Pôle d'endocrinologie, diabète et nutrition, UCL - (MGD) Service d'oncologie médicale, UCL - (MGD) Service de médecine nucléaire, UCL - (MGD) Service d'endocrinologie, UCL - (MGD) Service de chirurgie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'oto-rhino-laryngologie |
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty medicine.drug_class medicine.medical_treatment Review chemotherapy lcsh:RC254-282 Tyrosine-kinase inhibitor Thyroid carcinoma 03 medical and health sciences 0302 clinical medicine tyrosine kinase inhibitor Refractory Internal medicine medicine Thyroid cancer peptide receptor radionuclide therapy Chemotherapy business.industry Mortality rate Immunotherapy lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease mutations thyroid carcinoma 030104 developmental biology 030220 oncology & carcinogenesis Radionuclide therapy PRRT business |
| Zdroj: | Therapeutic Advances in Medical Oncology Therapeutic Advances in Medical Oncology, Vol 10 (2018) Therapeutic Advances in Medical Oncology, Vol. 10, p. 1-14 (2018) |
| ISSN: | 1758-8340 |
| Popis: | The incidence of thyroid cancer has increased markedly in recent decades, but has been stable in terms of mortality rates. For the most part, these cancers are treated with surgery, which may or may not be followed by radioactive iodine depending on the tumor subtype. Still, many of these cancers will recur and may be treated with radioactive iodine or another surgery. It is unclear what treatment is best for cases of locally advanced or metastatic thyroid cancer that are refractory to radioactive iodine. Chemotherapy has a very low response rate. However, in the past few years, several systemic therapies, primarily targeted, have emerged to improve the overall survival of these patients. Alternative treatments are also of interest, namely peptide receptor radionuclide therapy or immunotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|